@article{afd4ef70e8b348a882863f72a015177f,
title = "Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: Phase 2 results from the CheckMate 9X8 randomized clinical trial",
keywords = "gastrointestinal neoplasms, immune checkpoint inhibitors, immunotherapy, nivolumab, tumor biomarkers",
author = "Lenz, \{Heinz Josef\} and Aparna Parikh and Spigel, \{David R.\} and Cohn, \{Allen L.\} and Takayuki Yoshino and Mark Kochenderfer and Elena Elez and Shao, \{Spencer H.\} and Dustin Deming and Regan Holdridge and Timothy Larson and Eric Chen and Amit Mahipal and Antonio Ucar and Dana Cullen and Edwina Baskin-Bey and Tong Kang and Hammell, \{Amy B.\} and Jin Yao and Josep Tabernero",
note = "Publisher Copyright: {\textcopyright} Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.",
year = "2024",
month = mar,
day = "13",
doi = "10.1136/jitc-2023-008409",
language = "English",
volume = "12",
journal = "Journal for ImmunoTherapy of Cancer",
issn = "2051-1426",
number = "3",
}